Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 24Withdrawn 3Terminated 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × vinflunine × Clear all
NCT02845050 2018-02-13

JaNEO

Ligartis GmbH

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT00450515 2016-12-06

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Withdrawn
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00534807 2015-09-01

A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer

Bristol-Myers Squibb

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡